| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 892.4 | 873.2 | 792.4 |
| Other income | 3.2 | 2.4 | 2.8 |
| Total income | 895.6 | 875.6 | 795.2 |
| Profit before exceptional items & tax | 191.8 | 179.5 | 172.7 |
| Exceptional items | -35.9 | 0.0 | 0.0 |
| Profit before tax | 155.9 | 179.5 | 172.7 |
| Net profit | 187.1 | 143.3 | 134.5 |
| Operating margin | 17.4% | 20.5% | 21.7% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +39.10% |
|---|---|
| Net profit, quarter on quarter | +30.60% |
| Revenue, year on year | +12.60% |
| Operating profit, year on year | +11.00% |
| Operating profit, quarter on quarter | +6.50% |
NSE results filing, NSE: ERIS. Figures extracted from the filing.
Eris Lifesciences Ltd: key numbers
- Share price
- ₹1,174.00
- Market cap
- ₹16,288 Cr
- Revenue (annual)
- ₹3,129 Cr
- Net profit (annual)
- ₹619.5 Cr
- P/E (TTM)
- 23.0×Sector 46.5×
- Promoter holding
- 54.74%+0.60% QoQ
- FII holding
- 5.74%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Eris Lifesciences Ltd
All →Eris Lifesciences Investor Presentation: Key Takeaways
Q2 FY27 consolidated revenue ₹892 Cr (+12.6%), PAT ₹187 Cr (+39.2%), EBITDA margin 34.7%. H1 PAT ₹330 Cr (+27.3%). Zorvia out-licensing supports DBF gross margin.
Eris Lifesciences Board Meeting Date
Eris Lifesciences has scheduled a board meeting for October 26, 2026, to consider and approve its unaudited standalone and consolidated financial results for the quarter ending September.
Eris Lifesciences Other Announcement
Eris Lifesciences Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as required under SEBI regulations.
Eris Lifesciences Debt & Borrowing: ₹1,250 Cr
Eris Lifesciences Limited submitted its half-yearly reporting of debt securities for the period ended September 30, 2026. Two tranches of NCDs totaling ₹1,250 Crore remain outstanding.
- Value
- ₹1,250 Cr
Eris Lifesciences Management Change
Eris Lifesciences Limited announced the resignation of Mr. Krishnakumar Vaidyanathan from his roles as Executive Director and Chief Operating Officer. The resignation was effective September 30, 2026.
Eris Lifesciences Annual General Meeting
Eris Lifesciences Limited conducted its 20th Annual General Meeting on September 25, 2026. Shareholders transacted business including the adoption of audited financial statements and director re-appointments.